Connor Clark & Lunn Investment Management Ltd. lifted its position in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 71.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 711,278 shares of the biopharmaceutical company's stock after buying an additional 295,378 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned about 0.36% of Esperion Therapeutics worth $1,174,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in ESPR. Summit Wealth Group LLC acquired a new position in shares of Esperion Therapeutics during the 3rd quarter worth about $66,000. Versor Investments LP acquired a new position in Esperion Therapeutics during the third quarter worth approximately $44,000. Traphagen Investment Advisors LLC bought a new stake in Esperion Therapeutics in the third quarter valued at approximately $27,000. Boomfish Wealth Group LLC lifted its position in shares of Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company's stock valued at $58,000 after buying an additional 5,102 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of Esperion Therapeutics by 105.9% during the 3rd quarter. SG Americas Securities LLC now owns 77,049 shares of the biopharmaceutical company's stock worth $127,000 after acquiring an additional 39,635 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
ESPR has been the subject of several research reports. Needham & Company LLC cut their price target on Esperion Therapeutics from $8.00 to $6.00 and set a "buy" rating for the company in a report on Tuesday, August 13th. StockNews.com cut shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research note on Wednesday.
Get Our Latest Report on Esperion Therapeutics
Esperion Therapeutics Price Performance
NASDAQ ESPR traded down $0.03 on Thursday, reaching $2.54. The stock had a trading volume of 5,321,809 shares, compared to its average volume of 6,135,640. The company has a market cap of $500.48 million, a P/E ratio of -3.97 and a beta of 0.96. The firm has a fifty day moving average of $2.08 and a two-hundred day moving average of $2.16. Esperion Therapeutics, Inc. has a 1-year low of $1.16 and a 1-year high of $3.40.
Esperion Therapeutics Company Profile
(
Free Report)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Featured Stories
Before you consider Esperion Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.
While Esperion Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
